AI Terminal
Pentixapharm Holding AG
Earnings Release • Nov 12, 2025
8205_rns_2025-11-12_0ab7b472-8a62-4c2b-aa09-ba6fa7a61ffa.html
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Corporate | 12 November 2025 08:00
Pentixapharm Publishes 9-Month Figures for 2025
Pentixapharm Holding AG / Key word(s): 9 Month figures/Quarterly / Interim Statement
Pentixapharm Publishes 9-Month Figures for 2025
12.11.2025 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Pentixapharm Publishes 9-Month Figures for 2025
- Loss of the reporting period €12,7 million (attributed to research and development activities, personnel and other operating expenses)
- Revenue of the reported period €117 thousands
- Balance sheet total as of September 30, 2025: €43 million
- Adjusted Guidance for the fiscal year 2025: expected loss approximately €18 million (before: €23.5 million).
Berlin, Germany, 12 November 2025
The Executive Board of Pentixapharm Holding AG announced the following today:
Based on the newly published interim financial statements, the Group closed the first nine months of the 2025 fiscal year with a loss of EUR 12.7 million.
Based on current planning, the Company adjusts the guidan cefor the full 2025 fiscal. The Executive Board now expects a loss of approximately €18 million (before €23.5 million) as published on 06 November 2025.
This forecast includes research and development expenses as well as personnel and other operating expenses while potential income from out-licensing is not included in the forecast.
The full interim financial statements is available on the Pentixapharm Holding AG Investor Relations website: www.pentixapharm.com/investors/reports .
About Pentixapharm
Pentixapharm is an advanced clinical-stage biotech expanding the boundaries of radiopharmaceuticals. Headquartered in Berlin, Germany, the company develops first-in-class ligand- and antibody-based radiopharmaceuticals designed to transform patient care across oncology and beyond. Its late-stage pipeline is anchored by CXCR4-targeted programs, including a Phase 3-ready diagnostic candidate for primary aldosteronism and pioneering therapeutic programs in a number of hematological and solid cancers. Furthermore, Pentixapharm is advancing a next-generation antibody platform targeting CD24, an emerging immune-escape marker over-expressed in multiple hard-to-treat cancers. Complemented by reliable isotope supply from Eckert & Ziegler, and a robust global clinical network, Pentixapharm is uniquely positioned to deliver innovative radiopharmaceuticals that address high unmet need, improve patient outcomes, and create significant growth opportunities in one of the fastest-growing areas of precision medicine.
Pentixapharm Investor and Media Contact
12.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group .
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News
| Language: | English |
| Company: | Pentixapharm Holding AG |
| Robert-Rössle-Straße 10 | |
| 13125 Berlin | |
| Germany | |
| E-mail: | [email protected] |
| Internet: | https://www.pentixapharm.com/ |
| ISIN: | DE000A40AEG0 |
| WKN: | A40AEG |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2228042 |
| End of News | EQS News Service |
2228042 12.11.2025 CET/CEST